NHPV16 VLP vaccine induces human antibodies that neutralize divergent variants of HPV16

Virology. 2001 Jan 5;279(1):361-9. doi: 10.1006/viro.2000.0702.


Genital HPV genotypes are generally distinct serotypes, but whether variants within a genotype can represent serologic subtypes is unclear. In this study we used serum from human volunteers vaccinated with HPV16 L1 VLPs from variant 114K, to examine cross-neutralization of variants from each of the five major phylogenetic branches of HPV16. Recombinant Semliki Forest virus-derived pseudovirions for each variant were generated and combined with serum from vaccines, and the mixture was monitored for infectivity in a standard C127 cell focal transformation assay. Sera from all 10 VLP-immunized individuals had neutralizing activity against each of the variant pseudovirions. For each of the sera, variant titers differed by only fourfold or less from the median titer. Therefore, from a vaccine perspective, HPV16 variants belong to a single serotype. Vaccination with HPV16 114K L1 VLPs generates antibodies that should confer a similar degree of protection against all known phylogenetic branches of HPV16.

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I

MeSH terms

  • Antibodies, Viral / blood
  • Antibodies, Viral / immunology*
  • Cross Reactions
  • Humans
  • Immunization
  • Neutralization Tests
  • Papillomaviridae / classification
  • Papillomaviridae / genetics
  • Papillomaviridae / immunology*
  • Papillomavirus Infections / prevention & control
  • Phylogeny
  • Serotyping
  • Tumor Virus Infections / prevention & control
  • Viral Vaccines / administration & dosage
  • Viral Vaccines / immunology*
  • Virion / immunology*
  • Virion / metabolism
  • Virus Assembly


  • Antibodies, Viral
  • Viral Vaccines